Navigation Links
Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Date:5/14/2009

SEATTLE, May 14 /PRNewswire-FirstCall/ -- Dendreon Corporation today announced that Chief Executive Officer, Mitchell H. Gold, M.D., is a finalist for the Ernst & Young Entrepreneur Of The Year(R) 2009 Award in the Pacific Northwest. According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities. Mitchell Gold was selected as a finalist from nearly 65 nominations by a panel of independent judges. Award recipients will be announced at a special gala event on June 26, 2009 at the Seattle Sheraton.

"Dendreon is committed to improving the lives of cancer patients through the development of therapies that could someday offer safer and more effective treatment options to cancer patients in need, so I am thankful for this nomination. On behalf of all of our dedicated employees, we are honored to be recognized for these efforts to transform the way that cancer is treated," stated Dr. Gold.

The Ernst & Young Entrepreneur Of The Year awards program celebrates its 23rd anniversary this year. The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

Regional award recipients are eligible for consideration for the Ernst & Young LLP Entrepreneur Of The Year national program. Award recipients in several national categories, as well as the overall national Ernst & Young Entrepreneur Of The Year award recipient, will be announced at the annual awards gala in Palm Springs, California on November 14, 2009. The awards are the culminating event of the Ernst & Young Strategic Growth Forum, the nation's most prestigious gathering of high-growth, market-leading companies.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepren
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... ASA (OSE: ALGETA), the,cancer therapeutics company, announces ... the Tulane Cancer Center, New Orleans, has ... study of Alpharadin in men with,castration-resistant (also ... metastasized to the skeleton. , ... Prostate CAncer) study is a,double-blind, randomized, controlled ...
(Date:12/11/2009)... Gwathmey, Inc., a pre-clinical contract research organization and ... cardiovascular disease announces a new CEO. ... Ph.D., has joined Gwathmey as Chief Executive Officer. ... experience working with small businesses and the federal ... managed multimillion dollar portfolios for the National Institutes ...
(Date:12/11/2009)... of a NEW 2nd North American facility in Marietta, OH. The ... to support Esco,s growth in the North American market, specifically in ... , ... Hatboro, PA (PRWEB) December 11, 2009 -- ... in Marietta, OH. The facility will serve as a technical service, ...
(Date:12/10/2009)... -- Microban International, Ltd., the global leader ... with Sharp Imaging and Information Company of ... incorporate it,s third generation silver-based antimicrobial technology ... the calculator keys during manufacture, Microban ® ... damaging bacteria on the keys. ,, ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2
... Jan. 6 The Susan G. Komen for ... Center in Indianapolis has partnered with,BioStorage Technologies, Inc. ... BST will store a third of the tissue ... biorepository, including,samples being collected during the tissue bank,s ...
... Jan. 5 Beckman Coulter, Inc. (NYSE: ... marketer of products that simplify, automate, and innovate ... Beckman Coulter,s chairman, president and chief executive officer, ... Healthcare Conference on Monday, January 12, 2009 at ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext ... identifies, develops and commercializes differentiated products for ... received clearance from Canadian regulatory authorities to ... for nimotuzumab, its EGFR-targeting antibody, in combination ...
Other Biology Technology:BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative 2BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 2YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 3YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 4YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 5YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 6YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER 7
(Date:12/11/2009)... How does a cell manage to identify and degrade ... the body against serious diseases? The researchers Sabine C. ... Ernst Jarosch of the Max Delbrck Center for Molecular ... piece in this puzzle. In an enzyme complex that ... proteins, they discovered a scaffold regulating the identification and ...
(Date:12/11/2009)... , Montreal, December 11, 2009 Canadian ... cancer. In the December 11 edition of the prestigious ... de Montral and the Universit de Sherbrooke explain how ... activity of cytokines, hormones that are culprits in cancer-prone ... people exposed to asbestos. , "Excessive cytokine activity ...
(Date:12/11/2009)... December 11, 2009 Keystone Symposia on ... the appointment of five new Keystone Symposia Fellows ... enables five talented early-career life scientists (postdoctoral trainees ... program development process for one year. Fellows are ... as a commitment to promoting diversity in the ...
Breaking Biology News(10 mins):MDC researchers identify a scaffold regulating protein disposal 2Scientists identify natural anti-cancer defenses 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4avVaa World Health Care Products Inc Announces the completion of its first week of DRTV 120 60 second test commercials for Neuroskin 28R 29 Psoriasi 13755 1avVaa World Health Care Products Inc Announces the completion of its first week of DRTV 120 60 second test commercials for Neuroskin 28R 29 Psoriasi 13755 2Oncolytics Biotech 28R 29 Inc Announces Issuance of 32nd U S Patent 13754 1Oncolytics Biotech 28R 29 Inc Announces Issuance of 32nd U S Patent 13754 2FertilityTies Social Network for the Fertility Focused Unveils New Site Design Unique Features to Help Patients Find Fertility Doctors 26 More 55815 1FertilityTies Social Network for the Fertility Focused Unveils New Site Design Unique Features to Help Patients Find Fertility Doctors 26 More 55815 2
... is available in French . , ... California, Berkeley, have announced a major breakthrough in a ... first time the reversal of what is called epigenetic ... to develop a better understanding of gene regulation in ...
... their sedentary lifestyles and filter-feeding habits, clams have been ... upon their waters. These clams are silent no ... Island Sea Lab and her colleagues have reported in ... Biology . Using stable isotope techniques, Carmichael demonstrated ...
... The State University of New Jersey, has received a ... Foundation to establish the Institute for Food, Nutrition and ... President Richard L. McCormick announced his intention to establish ... University Community on Sept. 19. In that address, McCormick ...
Other Biology News:Plants display 'molecular amnesia' 2Plants display 'molecular amnesia' 3Rutgers receives US$10 million to establish Institute for Food, Nutrition and Health 2
... DNA Engine Dyad thermal cycler is ... (PCR). The chassis accommodates a variety ... assemblies), which hold different types and ... graphical programming with point-and-click navigation. Peltier ...
... IHC Select Immunophosphatase Secondary Detection System is ... Select Prediluted Primary Antibody reagents, which contain ... identification of antigens by light microscopy in ... Detection System may also be used with ...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
From the company that first brought you the chromatin immunoprecipitation (ChIP) kit, a new and improved kit, EZ-ChIP, is now available to make your experiments easier, quicker, and most importantly,...
Biology Products: